Neurotrope (OTCMKTS: NTRP), which is developing a disruptive therapy for the treatment of severe Alzheimer’s disease, has appointed an industry veteran to the board.
Dr Susanne Wilke will replace Larry Alstiel, who resigned to pursue a new, full-time professional opportunity.
"We are very pleased to welcome Susanne to our board," said Charles S. Ramat, President and CEO of Neurotrope.
"She is an industry veteran with a tremendous scientific background including a dual Ph.D. in Chemistry and Biochemistry and extensive understanding of various therapeutic areas.
"Susanne’s proven experience in scientific operations, strategic planning and managing the growth of emerging companies will prove invaluable as we advance Bryostatin-1 through our Phase 2b proof-of-concept trial in moderately-severe to severe Alzheimer’s disease.”
Wilke is the Co-founder and CEO of CrossBridge International, an advisory specializing in integrating proprietary scientific developments with sophisticated marketing and financing plans for biotech companies.
Dr. Wilke also served as Director of the Life Sciences group at Wombat Capital Markets SAS, a financial advisory firm specializing in cross-border transactions between the U.S. and Europe.
Neurotrope has successfully completed a Phase 2a trial, in which all primary endpoints were met, and is currently dosing patients in a Phase 2b proof-of-concept trial.